Atox Bio Infections Treatments Raises $23M

July 27, 2014 | Atox Bio, an Israeli company developing therapeutics for serious infections, announced that it raised $23 million in an investment round led by SR One with participation by Lundbeckfond Ventures and OrbiMed Israel. The funds will be used by Atox Bio to begin late stage clinical trials of AB1o3, a therapy treatment for Necrotizing Soft Tissue Infections or “flesh-eating bacteria,” as well as other serious infections. The AB103 immunomodulator was discovered by Prof. Raymond Kaempfer and Dr. Gila Arad.